📈 Economy · Next Month

Sanofi S.A. (EPA: SAN) beats Q2-2026 adjusted Business EPS consensus of approx. EUR 1.88 per share (July 30, 2026)

Hit ✦ AI-generated prediction Published on 22. July 2026 · Predicted for 30. July 2026 · Based on: Historical Cycle

Probability

67%

Sanofi publishes Q2-2026 results on July 30. Business EPS consensus ~€1.88; revenue consensus ~€11.39B (Chartmill/TipRanks, July 2026). In Q1 2026, Sanofi delivered double-digit sales and Business EPS growth, driven by Dupixent (leading biologic for atopic dermatitis/asthma, quarterly revenue >€4B) and Beyfortus (RSV infant protection, seasonally lower in Q2). Annual guidance: high single-digit sales growth, Business EPS slightly faster than sales. No prediction market found.

Data basis for this prediction

Chartmill / TipRanks: SAN Q2 2026 Business-EPS-Konsens 1,88 EUR, Umsatz-Konsens 11,39 Mrd. EUR (Jul 2026)
Sanofi Pressemitteilung: Q1 2026 – zweistelliges Umsatz- und Business-EPS-Wachstum (23.04.2026)
Sanofi IR: Q2-2026-Ergebnisankündigung für 30. Juli 2026 (sanofi.com)

Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.

Verdict: Hit

Sanofi berichtete am 30. Juli 2026 einen Business-EPS von €2,09 für Q2 2026 – deutlich über dem Konsens von ~€1,88 (Übertreffung um ca. +11%). Der Nettoumsatz lag bei €11,597 Mrd. und übertraf ebenfalls den Konsens von ~€11,39 Mrd. Haupttreiber: Dupixent (+37,6% auf €5,154 Mrd.) und starkes Pharma-Launch-Geschäft (+48,3%). Die Guidance für 2026 wurde daraufhin angehoben (Umsatzwachstum nun ~10% bei KWK). Quelle: Sanofi Pressemitteilung vom 30.07.2026 (globenewswire.com/news-release/2026/07/30/3335767) und Sanofi Investor Relations (sanofi.com/en/investors/financial-results-and-events/financial-results/q2-2026-results).

Related Predictions

📈 Economy ✦ AI

S&P 500 (^GSPC) closes above 7,450 points on 30 September 2026 (confirmed by NYSE closing price or Bloomberg by 30 September 2026)

The S&P 500 closed at 7,636.36 on 9 September 2026. Falling below 7,450 by month-end would require a 2.4% decline. Headwinds: Fed rate hike of 25bp on 16 September (CentralBank.Watch: 59% probability), August PPI above expectations (+5.4% YoY), Iran-Gulf risk premium. Stabilizing factors: hike largely priced in (Polymarket: 93% for zero 2026 cuts), Q2 earnings solid, no recession signals. Historically, a single 25bp September hike rarely causes a monthly decline above 2.5%.

73%

Next Month · Predicted for 30. Sep 2026

📈 Economy ✦ AI

US Federal Reserve raises the Federal Funds target range by 25 basis points on 16 September 2026 (FOMC decision)

Polymarket shows a 53% probability for a 25 basis point hike as of September 10, 2026. US Core CPI August 2026 (release September 11) is expected by market consensus to be above 3.0% YoY. The ECB raised its deposit rate by 25 bps to 2.50% on September 10, 2026 – an inflation-fighting signal that provides cover for the Fed. Against a hike: a mild slowdown in US industrial output. CME FedWatch also shows ~53% probability for a hike.

53%

Next Week · Predicted for 16. Sep 2026

📈 Economy ✦ AI

DAX 40 (XETRA) closes above 26,000 points on 30 September 2026 (confirmed by XETRA closing price or Bloomberg by 30 September 2026)

The DAX closed at 25,562 points on September 9, 2026. A gain of +1.7% is required by month-end. Headwinds: ECB rate hike to 2.50% (September 10), 53% FOMC hike probability (September 16), persistently high oil prices (~$101/barrel Brent) weigh on energy-intensive DAX heavyweights. Tailwinds: strong SAP cloud growth expected, robust US demand, EUR/USD at 1.1644 benefits exporters. Implied 30-day volatility (VDAX): ~16%, corresponding to a σ range of roughly ±5.5% by month-end — the 26,000 level falls within the central distribution.

48%

Next Month · Predicted for 30. Sep 2026